News
OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424
Poster Presentations to highlight the ongoing clinical studies targeting Globo …
OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic
TAIPEI, TAIWAN. APRIL 8, 2020– OBI Pharma has been closely …
OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
Second Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug …
OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 9, 2020 — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: …
OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
First Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug …
OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999.
TAIPEI, Taiwan, December 18, 2019 ─ OBI Pharma, a Taiwan …
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
First Clinical Trial to test the Safety and Efficacy of …
OBI Pharma Announces Poster Presentations at AACR 2019 for Novel Globo H Immuno-Oncology Therapeutics: OBI-888 and OBI-999
Poster Presentations to highlight on mechanism of action, anti-tumor efficacy …
New Scientific Research provides link between Globo-series glycosphingolipids (GSLs) antigens and tumor survival in Breast Cancer
Study supports the anti-Globo series Cancer pipeline under development by …
OBI Pharma, Inc. to Present at the J.P. Morgan Healthcare Conference
SAN FRANCISCO, CA. January 8, 2019 /PRNewswire/ — OBI Pharma, Inc., …